NASDAQ:ABUS

Arbutus Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy ABUS

*Your capital is at risk

$4.26

-0.220 (-4.91%)

At Close: Jun 02, 2026

Arbutus Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 74.97. In total, the insiders bought 15.12M and sold 239.19K ABUS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	74.97
● Buy	15.12M shares
● Sell	239.19K shares
82% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Feb 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 74.97. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 04, 2025 Sell	Common Shares S-Sale	Naftzger J. Christopher General Counsel And Cco	Officer	11 333 Value: $37.2K
Feb 04, 2025 Sell	Common Shares S-Sale	Mcelhaugh Michael J. Interim President & CEO	CEO / President	23 790 Value: $78.1K
Feb 04, 2025 Sell	Common Shares S-Sale	Sims Karen Chief Medical Officer	Officer	19 348 Value: $63.5K
Feb 04, 2025 Sell	Common Shares S-Sale	Hastings David C Chief Financial Officer	C-Suite Officer	22 183 Value: $72.8K
Aug 14, 2024 Buy	Common Shares M-Exempt	Manchester Keith S Director	Director	54 915 Value: $30.8K
Aug 14, 2024 Sell	Common Shares S-Sale	Manchester Keith S Director	Director	8 846 Value: $32.6K
Aug 14, 2024 Buy	Stock Option (Right to Buy) M-Exempt	Manchester Keith S Director	Director	54 915 Value: $30.8K
Aug 14, 2024 Buy	Stock Option (Right to Buy) M-Exempt	Manchester Keith S Director	Director	54 915 Value: $30.8K
Aug 14, 2024 Sell	Common Shares S-Sale	Manchester Keith S Director	Director	8 846 Value: $32.6K
Aug 14, 2024 Buy	Common Shares M-Exempt	Manchester Keith S Director	Director	54 915 Value: $30.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Burgess Daniel D Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Manchester Keith S Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Henriques Richard C Jr Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Meyers James R Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Rewolinski Melissa Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Torti Frank Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Torti Frank Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Rewolinski Melissa Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Meyers James R Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Henriques Richard C Jr Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Manchester Keith S Director	Director	67 000 Value: $219.8K
May 23, 2024 Buy	Stock Option (Right to Buy) A-Award	Burgess Daniel D Director	Director	67 000 Value: $219.8K
Feb 02, 2024 Sell	Common Shares S-Sale	Sims Karen Chief Medical Officer	Officer	4 358 Value: $10.1K
Feb 02, 2024 Sell	Common Shares S-Sale	Hastings David C Chief Financial Officer	C-Suite Officer	9 593 Value: $22.2K
Feb 02, 2024 Sell	Common Shares S-Sale	Sofia Michael J. Chief Scientific Officer	Officer	9 982 Value: $23.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARBUTUS BIOPHARMA CORPORATION

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...

Read Full Profile Here